Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326940 | 0.81 | DPP4 (0.39) | HCAR2AGBL2DPP4DPP9BACE1 | |
| SCHEMBL30641925 | 0.81 | DPP4 (0.39) | HCAR2AGBL2DPP4DPP9BACE1 | |
| SCHEMBL15991202 | 0.81 | SPR (0.48) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL18784193 | 0.81 | AGBL2 (0.37) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL257014 | 0.81 | DPP4 (0.39) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL31514824 | 0.81 | DPP4 (0.39) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL10328685 | 0.81 | KDM4E (0.41) | HCAR2KDM4EASPHKDM8KMO | |
| SCHEMBL1395991 | 0.81 | AGBL2 (0.41) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL8566219 | 0.81 | KDM4E (0.46) | HCAR2KDM4EASPHKDM8AGBL2 | |
| SCHEMBL1975713 | 0.79 | HCAR2 (0.42) | HCAR2KDM4EASPHKDM8AGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094939-A | Process for preparing 2-amino-3, 5-difluoropyridine or salts thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025093631-A1 | A PROCESS FOR PREPARING 2-AMINO-3,5-DIFLUOROPYRIDINE OR A SALT THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| CN-115057811-B | Preparation method of 2-bromomethyl-3, 5-difluoropyridine | 安庆朗坤药业有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-113880762-B | Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof | 河北农业大学 | 2023-02-21 | — | — | CN | claimed |
| CN-115057811-A | Preparation method of 2-bromomethyl-3, 5-difluoropyridine | 安庆朗坤药业有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-113880762-A | 1, 8-naphthalimide-containing triacylamine derivatives, and preparation method and application thereof | 河北农业大学 | 2022-01-04 | — | — | CN | claimed |
| EP-2511268-B1 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2016-07-13 | — | — | EP | claimed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| EP-1814880-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INT (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| EP-1814880-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-08-08 | — | — | EP | claimed |
| WO-2006051063-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL S. A. (ES) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | HCAR2 783/4885KDM4E 1800/4885ASPH 71/4885 |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | GABRA1, GABRA2, GABRA3 | HCAR2 64/4885KDM4E 2980/4885ASPH 3047/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | HCAR2 1071/4885KDM4E 2102/4885ASPH 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.